ジョンソン・エンド・ジョンソン、mCSPCでERLEADAがダロルタミド比で死亡リスク51％低減──24か月追跡のリアルワールド解析 | STELLANEWS.LIFE STELLANEWS.LIFE（ステラニュース・ライフ）は、科学や技術、医薬品分野における最新の研究成果や発見 | STELLANEWS.LIFE（ステラニュース・ライフ）は、科学や技術、医薬品分野における最新の研究成果や発見

Johnson & Johnson: ERLEADA Associated with 51% Lower Risk of Death Compared to Darolutamide in Real-World Analysis of Patients with mCSPC

stellanews.life/technology/8...

#ProstateCancer #ERLEADA #RealWorldEvidence #Oncology #JandJ #Apalutamide

New Study Shows ERLEADA® Significantly Lowers Death Risk for Prostate Cancer Patients A recent study indicates that ERLEADA® (apalutamide) significantly lowers the death risk in prostate cancer patients compared to darolutamide over 24 months.

New Study Shows ERLEADA® Significantly Lowers Death Risk for Prostate Cancer Patients #United_States #Horsham #Prostate_Cancer #ERLEADA #apalutamide

In a study using real-world data, Black patients with #mCSPC treated with #apalutamide achieved earlier and higher deep PSA responses than those receiving #abiraterone acetate, suggesting improved outcomes in an understudied population. jheor.org/article/151273 #HEOR #prostatecancer

Economic Evaluation of a Novel MicroRNA-Based Assay to Determine Risk of Late Genitourinary Radiation Toxicity in Patients With Prostate Cancer

In a real-world study of Black patients with metastatic prostate cancer, #apalutamide produced earlier and deeper PSA responses than #abiraterone acetate, highlighting potential clinical benefits in an understudied population. jheor.org/article/146844 #HEOR #ProstateCancer #BlackPatients

Lichenoid drug eruption and apalutamide: Analyses from pharmacovigilance databases and disproportionality analysis Lichenoid drug eruption and apalutamide: Analyses from pharmacovigilance databases and disproportionality analysis

Pharmacovigilance
Lichenoid drug eruption and apalutamide: Analyses from pharmacovigilance databases and disproportionality analysis
#Apalutamide #LichenoidDrugEruption #Pharmacovigilance
www.em-consulte.com/article/1717...